Adverum Biotechnologies Appoints Linda Neuman, M.D. as Vice President, Clinical Development
“Linda has significant drug development experience and has led multiple programs entering the clinic all the way to approval,” said
“I am excited to join this team of professionals driven to advance novel gene therapies to improve treatment options for patients,” said
On the date she commenced her employment, Adverum granted Dr. Neuman a stock option to purchase 92,000 shares of Adverum’s common stock pursuant to the inducement grant exception under NASDAQ Rule 5635(c)(4), as an inducement that is material to Dr. Neuman’ entering into employment with Adverum. The option will have a per share exercise price equal to the closing sales price of Adverum’s common stock on NASDAQ on the grant date, and will vest over four years, subject to Dr. Neuman’s continued service with Adverum. Pursuant to the terms of Dr. Newman’s employment with Adverum, Dr. Newman will also be granted a restricted stock unit award to acquire 64,000 shares of Adverum’s common stock which will vest over four yeaers, subject to Dr. Neuman’s continued service with Adverum.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that may offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Leone PattersonChief Financial Officer 650-665-7222 firstname.lastname@example.org
Source: Adverum Biotechnologies, Inc.